IP Verse

Combination Therapy For Inhalation Administration - EP4188327

The patent EP4188327 was granted to Chemo Research on May 28, 2025. The application was originally filed on Jul 30, 2021 under application number EP21755917A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4188327

CHEMO RESEARCH
Application Number
EP21755917A
Filing Date
Jul 30, 2021
Status
Granted And Under Opposition
Apr 25, 2025
Publication Date
May 28, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HIGHTONE MANAGEMENTOct 1, 2025GILL JENNINGS & EVERYADMISSIBLE

Patent Citations (31) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0315181
DESCRIPTIONEP1787639
DESCRIPTIONEP2515853
DESCRIPTIONEP2515854
DESCRIPTIONEP2515855
DESCRIPTIONEP3089735
DESCRIPTIONEP3096737
DESCRIPTIONEP3500241
DESCRIPTIONUS2003181478
DESCRIPTIONUS2007098644
DESCRIPTIONUS2007293460
DESCRIPTIONWO02083113
DESCRIPTIONWO0236106
DESCRIPTIONWO2006114379
DESCRIPTIONWO2007134968
DESCRIPTIONWO2012110462
DESCRIPTIONWO2014096115
DESCRIPTIONWO2015193213
DESCRIPTIONWO9701329
DESCRIPTIONWO9712687
DESCRIPTIONWO9827959
INTERNATIONAL-SEARCH-REPORTUS2003181478
INTERNATIONAL-SEARCH-REPORTWO2017089404
INTERNATIONAL-SEARCH-REPORTWO9701329
OPPOSITIONUS2008041369
OPPOSITIONWO2015189168
OPPOSITIONWO2017089404
OPPOSITIONWO2022023515
OTHEREP3151812
OTHERUS2006127322
OTHERWO2017089404

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Early Intervention Efficacy in COPD", ClinicalTrials.gov, ID: NCT04249310, (20220614), pages 1 - 7, ClinicalTrials.gov, ID: NCT04249310, URL: https://clinicaltrials.gov/study/NCT04249310?term=NCT04249310&rank=1&tab=table, (20231003), XP093088147
OPPOSITION- Anonymous, "Trimbow - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS", EMA, (20170717), XP093324876
OPPOSITION- Wachtel Herbert, Kattenbeck Sabine, Dunne Stephen, Disse Bernd, "The Respimat® Development Story: Patient-Centered Innovation", Pulmonary Therapy, (20170601), vol. 3, no. 1, doi:10.1007/s41030-017-0040-8, ISSN 2364-1754, pages 19 - 30, XP093324873
OPPOSITION- Dalby, R. Spallek, M. Voshaar, T., "A review of the development of Respimat^(R) Soft Mist(TM) Inhaler", International Journal of Pharmaceutics, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (20040928), vol. 283, no. 1-2, doi:10.1016/j.ijpharm.2004.06.018, ISSN 0378-5173, pages 1 - 9, XP004560626
OPPOSITION- Newman S.P., Steed K.P., Reader S.J., Hooper G., Zierenberg B., "Efficient Delivery to the Lungs of Flunisolide Aerosol From a New Portable Hand-Held Multidose Nebulizer", Journal of pharmaceutical sciences, Elsevier Inc, (19960901), vol. 85, no. 9, doi:10.1021/js950522q, ISSN 0022-3549, pages 960 - 964, XP093088156
OPPOSITION- Voshaar T., Hausen T., Kardos P., Köhler D., Schultze-Werninghaus G., Schürmann W., Vogelmeier C., "Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD", PNEUMOLOGIE, THIEME, STUTTGART, DE, DE , (20050101), vol. 59, no. 01, doi:10.1055/s-2004-830161, ISSN 0934-8387, pages 25 - 32, XP093324870
OPPOSITION- Pitcairn Gary, Reader Sandie, Pavia Demetri, Newman Steve, "Deposition of Corticosteroid Aerosol in the Human Lung by Respimat® Soft Mist™ Inhaler Compared to Deposition by Metered Dose Inhaler or by Turbuhaler® Dry Powder Inhaler", Journal of Aerosol Medicine, (20050901), vol. 18, no. 3, doi:10.1089/jam.2005.18.264, ISSN 0894-2684, pages 264 - 272, XP093088152
OPPOSITION- Connelly Dawn, "Blue, brown and now green", The Pharmaceutical Journal, (20200623), vol. 304, doi:10.1211/PJ.2020.20208093, page 7938, XP093324878
OPPOSITION- Paula Anderson, "Use of Respimat� Soft Mist? Inhaler in COPD patients", The International Journal of Chronic Obstructive Pulmonary Disease, Dove Medical Press Ltd., New Zealand, New Zealand , (20060101), vol. 1, no. 3, doi:10.2147/copd.2006.1.3.251, ISSN 1176-9106, pages 251 - 259, XP055730734
OPPOSITION- Donald Tashkin, "A review of nebulized drug delivery in COPD", International Journal of Chronic Obstructive Pulmonary Disease, Volume 11, doi:10.2147/COPD.S114034, pages 2585 - 2596, XP055633158
OPPOSITION- Hodder Rick, Reese Pat Ray, Slaton Terra, "Asthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler", The International journal of chronic obstructive pulmonary disease, Albany, Auckland : DOVE Medical Press, (20090101), vol. 4, doi:10.2147/COPD.S3452, ISSN 1178-2005, pages 225 - 232, XP093324875
OTHER- Anonymous, "Early Intervention Efficacy in COPD", ClinicalTrials.gov, ID: NCT04249310, (20220614), pages 1 - 7, ClinicalTrials.gov, ID: NCT04249310, URL: https://clinicaltrials.gov/study/NCT04249310?term=NCT04249310&rank=1&tab=table, (20231003), XP093088147
OTHER- Newman Stephen P., "Use of Gamma Scintigraphy to Evaluate the Performance of New Inhalers", JOURNAL OF AEROSOL MEDICINE, (19990101), vol. 12, no. 1, pages S - S-31, XP093088160
OTHER- Dalby, R. Spallek, M. Voshaar, T., "A review of the development of Respimat^(R) Soft Mist(TM) Inhaler", International Journal of Pharmaceutics, NL , (20040928), vol. 283, no. 1-2, doi:10.1016/j.ijpharm.2004.06.018, ISSN 0378-5173, pages 1 - 9, XP004560626
OTHER- C.L. Leach, "Improved delivery of inhaled steroids to the large and small airways", Respiratory Medicine, AMSTERDAM, NL, (19980601), vol. 92, no. Supp A, doi:10.1016/S0954-6111(98)90211-6, ISSN 0954-6111, pages 3 - 8, XP055706349
OTHER- Ali Hany S. M., York Peter, Blagden Nicholas, Soltanpour Shahla, Acree William E., Jouyban Abolghasem, "Solubility of Budesonide, Hydrocortisone, and Prednisolone in Ethanol + Water Mixtures at 298.2 K", JOURNAL OF CHEMICAL AND ENGINEERING DATA, US , (20100114), vol. 55, no. 1, doi:10.1021/je900376r, ISSN 0021-9568, pages 578 - 582, XP093105363
OTHER- Newman S.P., Steed K.P., Reader S.J., Hooper G., Zierenberg B., "Efficient Delivery to the Lungs of Flunisolide Aerosol From a New Portable Hand-Held Multidose Nebulizer", Journal of Pharmaceutical Sciences, US , (19960901), vol. 85, no. 9, doi:10.1021/js950522q, ISSN 0022-3549, pages 960 - 964, XP093088156
OTHER- N. R. Labiris; M. B. Dolovich, "Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications", British journal of clinical pharmacology, GB , (20030820), vol. 56, no. 6, doi:10.1046/j.1365-2125.2003.01893.x, ISSN 0306-5251, pages 600 - 612, XP071598955
OTHER- Zierenberg Bernd, "Optimizing the in Vitro Performance of Respimat", Journal of Aerosol Medicine, (19990901), vol. 12, no. s1, doi:10.1089/jam.1999.12.Suppl_1.S-19, ISSN 0894-2684, pages S-19 - S-24, XP009550076
OTHER- Newman Stephen P., "Use of Gamma Scintigraphy to Evaluate the Performance of New Inhalers", Journal of Aerosol Medicine, (19990901), vol. 12, no. s1, doi:10.1089/jam.1999.12.Suppl_1.S-25, ISSN 0894-2684, pages S - S-31, XP009550079
OTHER- Pitcairn Gary, Reader Sandie, Pavia Demetri, Newman Steve, "Deposition of Corticosteroid Aerosol in the Human Lung by Respimat® Soft Mist™ Inhaler Compared to Deposition by Metered Dose Inhaler or by Turbuhaler® Dry Powder Inhaler", Journal of Aerosol Medicine, (20050901), vol. 18, no. 3, doi:10.1089/jam.2005.18.264, ISSN 0894-2684, pages 264 - 272, XP093088152

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents